Under the agreement, Amedica/US Spine will distribute BioDlogics’ stem cell products for spinal fusion, adhesion barrier and nerve protection. Ben Shappley, president and CEO of Amedica/US Spine, says the agreement will increase the company’s presence in the biologic market and complements the line of MC2 Silicon Nitride spine spacers it already offers.
The BioDfence and BioDfactor products are packaged at an FDA-registered tissue bank.
Read more about the agreement between Amedica/US Spine and BioDlogics.
Read more about Amedica/US Spine:
– Amedica Acquires US Spine
– Amedica Patents Motion-Preserving Spine Implant
– Amedica Receives Patent for Knee Prosthesis
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
